Salute e Benessere
Procare Health released results from their latest clinical trial, Paloma 2, confirming the efficacy of Papilocare®, a vaginal gel designed to repair low-grade cervical lesions and to clear Human Papillomavirus (HPV)
MADRID , March 25, 2025 /PRNewswire/ --
The clinical trial, conducted in , involved with an average age of . All participants tested positive for and presented with low-grade cervical lesions. The trial compared two groups: one received intensive treatment with , while the other followed standard clinical practice (watchful approach).
The results demonstrated that of the women treated with cleared the virus after a , compared to in the control group. This difference was statistically significant ( ), reinforcing earlier findings from the trial, which reported an repaired cervical lesions. Additionally, the therapeutic benefit persisted at the , confirming Papilocare®'s mid-term efficacy in reducing HPV persistence.
Papilocare® incorporates a unique formulation based on the natural Asian fungus . Its advanced delivery technology utilizes and , ensuring effective absorption and sustained action on cervical tissue. The gel forms a protective barrier over the cervical mucosa, acting as a that prevents HPV integration.
The trial also confirmed that Papilocare® is . The treatment regimen included , followed by . No significant adverse effects were reported during the study.
For years, low-grade HPV-induced cervical lesions were managed with a watchful approach rather than proactive intervention. According to , an expert in cervical pathology at HM Gabinete Velázquez, Madrid "The results mark a significant turning point by offering an effective noninvasive active therapeutic approach to reduce HPV persistence and prevent cervical lesion progression."
Cervical cancer is a major public health concern, with approximately and reported annually in the UK. Current preventive strategies emphasize , , and of precancerous lesions. While vaccination effectively prevents up to seven high-risk HPV genotypes, Papilocare® offers a complementary therapeutic option for patients who have already contracted the virus.
Approximately of Spanish women aged 18-65 are HPV-positive. While most clear the virus naturally within , persistent infection poses the greatest risk of developing cervical lesions that can progress to cancer. Papilocare®'s proven efficacy in accelerating HPV clearance offers a valuable tool in reducing these risks.
Founded in , is a Spanish pharmaceutical company specializing in natural, evidence-based solutions for women's health. With over involving , Papilocare® is now available in more than worldwide.
The trial reinforces Papilocare® as a scientifically validated treatment option for reducing HPV persistence and promoting cervical health.